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Porphobilinogen deaminase (PBGD), the third enzyme in the heme biosynthesis,
catalyzes the sequential coupling of four porphobilinogen (PBG) molecules into a
heme precursor. Mutations in PBGD are associated with acute intermittent
porphyria (AIP), a rare metabolic disorder. We used Fourier transform ion cyclo-
tron resonance mass spectrometry (FT-ICR MS) to demonstrate that wild-type
PBGD and AIP-associated mutant R167W both existed as holoenzymes (Eholo)
covalently attached to the dipyrromethane cofactor, and three intermediate
complexes, ES, ES2, and ES3, where S represents PBG. In contrast, only ES2 was
detected in AIP-associated mutant R173W, indicating that the formation of ES3
is inhibited. The R173W crystal structure in the ES2-state revealed major rear-
rangements of the loops around the active site, compared to wild-type PBGD
in the Eholo-state. These results contribute to elucidating the structural pathogen-
esis of two commonAIP-associatedmutations and reveal the important structural
role of Arg173 in the polypyrrole elongation mechanism.
INTRODUCTION
Porphobilinogen deaminase (PBGD; EC 2.5.1.61), also known as hydroxymethylbilane synthase (HMBS), is
the third enzyme in the heme biosynthetic pathway. Heme is an important biomolecule that participates in
many essential functions in humans, in particular, oxygen transport in blood. PBGD catalyzes four consec-
utive reactions to convert porphobilinogen (PBG) into hydroxymethylbilane (HMB), a linear tetrapyrrole
heme precursor. Mutations in the HMBS gene are associated with a genetic metabolic disorder known
as acute intermittent porphyria (AIP), giving reduced heme production and severe metabolic and neuro-
logical symptoms (Bonkovsky et al., 2019). Missense mutations constitute 32% of the more than 500
known mutations of human PBGD (hPBGD), and cause destabilization of the enzyme and/or a direct effect
on catalysis (Chen et al., 2019; Scott et al., 1988). PBGD is expressed in a tissue-specific manner, with two
isoforms produced by different promotor usage and alternative splicing, with the ubiquitously expressed
housekeeping PBGD containing 17 extra residues in the N-terminus compared to the erythroid-specific iso-
form (Grandchamp et al., 1987). However, the catalytic activity of these two isoforms is similar, and the extra
N-terminal region has no known function (Brons-Poulsen et al., 2005).
A wealth of structural and functional information is available for both wild-type (wt) and mutant PBGDs,
including several three-dimensional structures as well as kinetic, biophysical, and computational data
(Awan et al., 1997; Bung et al., 2019; Bustad et al., 2013; Hadener et al., 1999; Louie et al., 1992; Niemann
et al., 1994; Pluta et al., 2018; Roberts et al., 2013; Shoolingin-Jordan et al., 1996; Song et al., 2009). The
crystal structures of wt-PBGD have so far been solved for human (PDB: 3ECR, 5M7F (Pluta et al., 2018;
Song et al., 2009)), Escherichia coli (PDB: 1PDA (Louie et al., 1992)), Arabidopsis thaliana (PDB: 4HTG
(Roberts et al., 2013)), Bacillus megaterium (PDB: 4MLV (Azim et al., 2014)) and Vibrio cholera (PDB:
5H6O (Uchida et al., 2018)) enzymes, showing the same basic topology with three separate domains (Fig-
ure 1A). A deep cleft within the active site connects domains 1 and 2 (residues 1–114 and 120–212,
respectively, in hPBGD) by several interactions that stabilize the overall structure. The holoenzyme (Eholo)
carries a dipyrromethane (DPM) cofactor, which is covalently linked to a conserved cysteine residue
(Cys261 in hPBGD) through a thioether bond (Song et al., 2009). Domain 3 (residues 241–361) contains
a loop that includes the active site Cys261. DPM derives from two PBG molecules, and functions as aniScience 24, 102152, March 19, 2021 ª 2021 The Author(s).
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Crystal structure of hPBGD wt-Eholo and schematic representation of the polypyrrole elongation
mechanism
(A) Overall representation of the crystal structure of wt-hPBGD (PDB: 7AAJ), providing the expected holoenzyme (Eholo)
with three separate domains (domain 1 is presented in red, domain 2 in light brown, and domain 3 in green). The bound
dipyrromethane (DPM) cofactor is shown in a brown stick representation.
(B) Schematic representation of the general understanding of the mechanism of a single step in the polypyrrole
elongation.
(C) The polypyrrole elongation catalyzed by PBGD. PBGD with attached DPM (Eholo) subsequently binds four
porphobilinogen (PBG) substrates (S), and generates the enzyme intermediates ES, ES2, ES3, and ES4. The linear product,
hydroxymethylbilane (HMB), is released by hydrolysis and cyclized by the next enzyme in the heme biosynthesis. The
sidechains of the substrates, acetate (CH2CO2H) and propionate (CH2CH2CO2H) are denoted Ac and Pr, respectively.
Figure 1C is modified from (Jordan and Woodcock, 1991).
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Articleanchor for the sequential coupling of additional four PBG molecules by deamination (Figure 1B) (Layer
et al., 2010). When the polypyrrole chain elongation is complete, HMB is released by hydrolysis of the
thioether bond, leaving DPM behind, after which the cycle starts again (Figure 1C). As a part of the
head-to-tail polymerization process, several covalent enzyme-substrate intermediates are formed, first
described in the early 1980s (Anderson and Desnick, 1980; Berry et al., 1981; Jordan and Berry, 1981),
which are usually denoted as ES, ES2, ES3, and ES4, where E represents Eholo, and S represents the re-
acted PBG molecule.
The exact mechanism of the polypyrrole formation is still not completely understood. Recently, Pluta
et al. published crystal structures of the wt-hPBGD Eholo and its ES2 intermediate (PDB: 5M7F and
5M6R, respectively (Pluta et al., 2018)). These structures allowed the authors to propose a reaction mech-
anism for PBGD, highlighting the importance of the flexible loop Leu257–Val263 that gives room for the
elongation from Eholo to ES2. This is contrary to recent molecular dynamics (MD) simulations comple-
mented with site-directed mutagenesis where very little structural rearrangements upon polypyrrole for-
mation were associated with catalysis and the authors suggested that only a few specific residues,
namely Asp99 and Arg26 (Figure 1B), would be responsible for the elongation process (Bung et al.,
2014, 2018, 2019).
In this work, we analyzed wt-hPBGD and two recurrent AIP-associated mutants using high-resolution elec-
trospray ionization Fourier transform ion cyclotron resonance mass spectrometry (ESI FT-ICRMS) and X-ray
crystallography. The mutants, R167W and R173W, have different mechanistic effects, but are both associ-
ated with a severe AIP phenotype (Andersson et al., 2000; Bustad et al., 2013; Mustajoki et al., 2000). R167W
represents a catalytically impaired mutant owing to high Km for PBG and low Vmax leading to slower poly-
pyrrole elongation (Bustad et al., 2013; Fu et al., 2019; Solis et al., 2004). R173W, on the other hand, is cata-
lytically deleterious with an activity of 0.6% relative to wt and indeterminable Km and Vmax, together with an
obstructed substrate elongation (Bustad et al., 2013; Fu et al., 2019). Our results indicate that Arg173 is
essential for the formation of the ES3 intermediate, with an important structural role that is relevant for
its catalytic contribution. Considering this, we provide unique molecular details on the reaction intermedi-
ates for wt-hPBGD and the AIP-associated mutants and shed light on the catalytic and pathogenic
mechanisms.RESULTS
Characterization of enzyme intermediates in the wild-type hPBGD
The recombinantly expressed and purified hPBGD typically consists of a heterogeneous mixture of
enzyme-intermediates (Bustad et al., 2013; Shoolingin-Jordan et al., 2003), and isolation of each interme-
diate is not customarily performed. In the ESI-FT-ICR mass spectra of wt-hPBGD, all the expected enzyme
intermediates, i.e., Eholo, ES, ES2, and ES3, were detected (Figures 2A and 2B). In addition, a small amount
of the apoenzyme (Eapo) was also observed, which is surprising since Eapo is expected to be highly unstable
and has not been observed in earlier studies of PBGD kinetic intermediates. However, ESI-FT-ICR MS is a
much more sensitive detection technique than most other biophysical methods previously applied. The
experimentally determined masses of the intermediates perfectly matched with the theoretical masses
considering covalently linked reaction intermediates. The greatest abundance was observed for ES2, fol-
lowed by Eholo, ES3, and ES complexes (Figure 2B), corroborating that ES2 is kinetically the most stable re-
action intermediate. As expected, ES4 was not detected at all, as this intermediate is short-lived and is
rapidly hydrolyzed into the linear HMB product (Warren and Jordan, 1988). This observed distribution is
consistent with results from earlier studies (Bustad et al., 2013; Niemann et al., 1994; Shoolingin-Jordan
et al., 2003), demonstrating the ability of ESI-FT-ICR MS to separate and directly identify different co-exist-
ing enzyme-substrate intermediates through intact protein mass analysis. In addition, the mass accuracy
was high enough to directly distinguish between the reduced (DPM) and the oxidized (dipyrromethene)
form of the cofactor (i.e., 2 Da mass difference in a 40 kDa protein), and our results conclusively indicated
that the DPM cofactor existed exclusively in its reduced DPM form (Figure S1). There was no evidence of
further cofactor oxidation to a dipyrromethanone (+16 Da) form, which has been observed in the crystal
structure of B. megaterium PBGD and suggested to be responsible for the pink color of the enzyme in so-
lution (Azim et al., 2014).
We also confirmed that the substrate binding exclusively occurs through the covalent linkage to Cys261.
The tryptic digestion of wt-hPBGD resulted in nearly 100% sequence coverage with 58 identified specificiScience 24, 102152, March 19, 2021 3
Figure 2. High-resolution mass spectrometry of hPBGD enzymes
The ESI FT-ICR mass spectra were measured at denaturing conditions with 5 mM protein.
(A) Broadband mass spectrum of wt-hPBGD with numbers denoting different protein ion-charge states. A wide charge
state distribution from 18 + to 45+ is consistent with the protein being fully unfolded.
(B) Charge-deconvoluted mass spectrum showing peaks representing different enzyme-intermediates in wt-hPBGD.
(C) and (D) Charge-deconvoluted mass spectra of the hPBGD mutants R167W and R173W, respectively. The peaks
representing different enzyme-intermediates are assigned.




Articletryptic peptides (Table S1 and Figure S2). The peptide 226–272 was only identified when the tetrapyrrole
(corresponding to ES2) was included as the variable modification in the peptide fingerprinting.
Furthermore, a comparison of the ESI FT-ICR mass spectra of wt-hPBGD in denaturing (Figure 2B) and
native conditions (10 mM ammonium acetate pH 6.9; Figure S1) showed similar enzyme-intermediates,
thus, implying that all enzyme-substrate complexes are covalent in nature. The only difference between
the spectra was that weak signals were detected atm/z 3800–4500 at native conditions, possibly represent-
ing a very low proportion of a noncovalent protein dimer (Figure S1).
The relative amounts of the reaction intermediates are different for the AIP-associated
hPBGD mutants compared to the wild-type enzyme
Two active site hPBGD mutants, R167W and R173W, both showing catalytic dysfunction and a high asso-
ciation with AIP (Bustad et al., 2013), were selected for mass spectrometric analysis. For R167W, the
observed enzyme intermediates by ESI FT-ICR MS in denaturing conditions were like wt-hPBGD (Figures
2B and 2C). However, a much higher relative abundance was seen for Eholo as compared to the other reac-
tion intermediates, suggesting that the mutation R167W causes a perturbed binding of the first PBG mole-
cule to the Eholo and decreasing the rate of HMB synthesis.
In contrast, only a single reaction intermediate was observed for R173W, with a mass corresponding to ES2
(Figure 2D). This result is consistent with the previous native PAGE analysis of this mutant with a single pro-
tein band, and a mild conformational defect as seen by thermal circular dichroism spectroscopy and differ-
ential scanning fluorimetry (Bustad et al., 2013). This suggests that productive binding of a third substrate
molecule is inhibited when Arg173 is mutated to tryptophan, leading to the accumulation of the ES2 inter-
mediate without turnover, in agreement with the more severe catalytic dysfunction (<1% residual activity)
and a more severe AIP phenotype for the R173W than for the R167W mutant (Fu et al., 2019). Additional
trypsin digestion experiments verified that the cofactor or the growing pyrrole chain were bound exclu-
sively to Cys261 also in R173W-hPBGD (Table S2 and Figure S3).4 iScience 24, 102152, March 19, 2021
Figure 3. The crystal structure of hPBGD wt-Eholo and R173W-ES2
(A) Overall cartoon representation of wt-Eholo (gray; PDB: 7AAJ) andmutant R173W-ES2 (blue; PDB: 7AAK) superimposed.
DPM cofactor with C1 and C2 units of wt-Eholo is shown in brown and elongation product of R173W-ES2 including S1 and
S2 units is shown in green. The mutated residue studied here, R173W, is shown as sticks. The cofactor-binding loop and
cofactor are rearranged (red arrow) in the structure, allowing incoming substrate pyrroles (S1 and S2) substitute C1 and C2
at equal positions as in the Eholo.
(B) The active-site loop (residues 57–74) orientation in wt-ES2 (PDB: 5M6R; dark gray (Pluta et al., 2018)) is compared to the
loop orientation in R173W-ES2 (red). Formed ⍺21 helixes are labeled. Close-up also shows the movement of the cofactor-
binding loop (orange; residues 257–263), and the elongation product in the R173W mutant. The position of cofactor-
binding Cys261 has been indicated with labels C261-Eholo and C261-ES2 for wt-Eholo and R173W-ES2 structures,
respectively. Glycerol (GOL) partially filling the solvent cavity under the cofactor-binding loop in the R173W-ES2 structure
is shown as sticks (yellow).




ArticleHigh-resolution crystal structures provide important insights into the catalytic mechanism
To obtain further structural insight into the catalytic mechanism we crystallized wt-hPBGD and the AIP-
associated mutant R173W. The three-dimensional structures were determined to 1.8 (PBD: 7AAJ) and
1.7 Å resolution (PBD: 7AAK), respectively (Table 1). The overall three-domain structure of both proteins,
as well as the active site architecture of wt-hPBGD, are very similar to those of the previously published
structure, with an RMSD of 0.256 Å between monomers of our wt-hPBGD and PDB: 3ECR (Figure 1A).
Furthermore, both our structures contain two monomers in the asymmetric unit without indication of
dimerization as also supported by the mass spectrometry results showing that except for minor dimeric
forms, Eholo and the other enzyme-intermediates are monomeric. Our crystallization trials for the R167W
mutant were unsuccessful. However, a previously published structure of the R167Q mutant (PDB: 3EQ1
(Gill et al., 2009)) also represents the Eholo-state only, as the wt-hPBGD.
In agreement with the ESI FT-ICR MS analyses of wt-hPBGD, a fully reduced covalently attached DPM oc-
cupies the active site cleft, showing a 120 angle between the pyrrole rings, instead of the coplanar
conformation of oxidized DPM (Azim et al., 2014). The crystal structure only represents the Eholo-state
and is denoted as wt-Eholo hereafter. The binding mode (Figures 3 and 4) and interactions (Figures 5A
and 6A) of DPM are the same as in the previously published structure (PDB: 3ECR). Electron density is
observed for the two neighboring residues of Cys261, i.e., Gly260 and Gly259, which are also visible in
another recent structure of wt-hPBGD (PDB: 5M7F) but not in the earlier structure (PDB: 3ECR). The vari-
ability of the electron density quality as well as elevated B-factors indicate a dynamic nature of the residues
Leu257–Val263 that constitute the cofactor-binding loop (Figure 3B). Electron density is missing for the first
18 residues at the N-terminus and for the active-site loop residues Ser57–Lys74. Unfortunately, surface
exposed residues in flexible sidechains, including Arg167, are not described in the electron density
maps. This prevented us to draw further conclusions on the possible catalytic role of this residue.
The structure of themutant R173W-hPBGD agrees with the ESI FT-ICRMS analysis, representing only ES2 in
its reduced form (denoted R173W-ES2) and thus revealing for the first time an AIP-associated mutant trap-
ped in a reaction intermediate state. Electron density for the N-terminus was again missing, and the main
chain atoms of the active-site loop Ser57–Lys74 could be built only in subunit A (Figure 4A). Within this
loop, residues Lys62–Thr66 form a short a-helix (Figure 3B) shown with individual residues in the electron
density map in Figure 4A. Crystal packing prevents the loop in the other subunit, B, to adopt the same
conformation as in subunit A, however, only traces of the electron density for the loop in subunit B caniScience 24, 102152, March 19, 2021 5
Figure 4. Electron density for the structural features
Calculated 2mFo-DFc-electron density for (A) the active-site loop in R173W-ES2, (B) bound cofactor in wt-Eholo and (C) the




Articlebe seen andwas thus not built. Trp173 has different side chain conformations in the two subunits andhas two
alternative conformations in subunit A (Figure S4). In addition, Ser146 has alternative conformations and
seems to move in concert with Trp173 (Figure S4). We also discovered rearrangement in the helix a22 (res-
idues 170–179; Figure S4) in subunit B. This rearrangement allows Trp173 to adopt a completely different
conformation than seen in subunit A. From this point forward, we will only discuss the structure of subunit
A, unless otherwise stated.
The additional pyrrole rings seen in the R173W-ES2 structure are denoted S1 and S2, in addition to the C1
and C2 rings of the original DPM cofactor (Figures 4, 5, and 6). The incorporation of S1 and S2 in R173W-ES2
causes a major rearrangement in the cofactor-binding loop Leu257–Val263 including Cys261 to which the
reaction intermediate is covalently bound. In contrast to wt-Eholo, the active-site loop Ser57–Lys74 in
R173W-ES2 is reoriented toward the C-terminal helix, a33, allowing the accommodation of the additional
pyrrole rings in the active site cleft between the domains 1 and 2 (Figure 3). The created cavity is not filled
by the relocated C1 and C2 rings, and in the structure, a glycerol molecule occupies the space between C1
and the protein core (Figure 3). Because of this rearrangement, the new pyrrole rings S1 and S2 take the
original places of the C1 and C2 rings of the DPM cofactor in the wt-Eholo structure (Figures 3B and 5).
Structural comparison between R173W-ES2, wt-Eholo and wt-ES2
All three domains participate in the formation of the interaction network around the cofactor in Eholo or the
four pyrrole rings in ES2 in the active site. These interactions are described in detail in Table 2, and Figures 5
and 6. It is noticeable that the interactions change for C1 and C2 when S1 and S2 subsequently are incor-
porated in the R173W-ES2 structure. Thus, C1 interacts with Thr102 and Val215 (main chain), and C2 inter-
acts with Lys98 (main chain) and Ser262 (Figures 5 and 6). S1, which in R173W-ES2 occupies the original po-
sition of C1 in Eholo, interacts with Ser147 and Arg149 through the acetate side chain. The propionate side6 iScience 24, 102152, March 19, 2021
Figure 5. Stick representation of the active site
The image shows active site interactions of (A) our wt-Eholo (side chains gray and substrate brown), and (B) R173W-ES2
(side chains blue and substrate green) superimposed with wt-ES2 (PDB: 5M6R; side chains dark gray and substrate pink
(Pluta et al., 2018)). Incoming PBG units in the ES2 intermediates substitute C1 and C2 at equal positions as in the Eholo.




Articlechain of S1 does not make hydrogen bonds to any atoms in the R173W-ES2 structure. S2 occupies the
equivalent position of C2 in Eholo, where the acetate side chain interacts with Arg98, Arg150 and Ala189
and the propionate side chain creates hydrogen bonds with Ser96, Arg195, and Gly218. Lys98 forms salt
bridges with both acetate side chains of rings S1 and S2. Interestingly Asp99 interacts with both pyrrole
N atoms of C1 and C2 in wt-Eholo, whereas in the R173W-ES2 there is only an interaction to pyrrole N in
S1 (Table 2 and Figures 5 and 6).
The active-site loop Ser57–Lys74 in R173W-ES2 has also been observed in the Eholo structure of PBGD from
A. thaliana (AtPBGD; PDB: 4HTG) and in human wt-hPBGD recently crystallized in the ES2-state (wt-ES2;
PDB: 5M6R). The loop appears to close the active site like a lid, and is mostly unstructured in AtPBGD, whereas
it includesamoredefineda-helix inbothR173W-ES2 (Figure3B) andwt-ES2 (PDB: 5M6R). Inwt-ES2 (PDB: 5M6R),
the a-helix is three residues longer and the loop partially covers the active site, without direct interaction with
the cofactor or substrates (Pluta et al., 2018). In R173W-ES2 presented here, the active-site loop is oriented in a
significantly different conformation, partially facing away from the surface with Lys74 establishing several inter-
actions with C2 and S1 (Figures 5 and 6). In wt-ES2 (PDB: 5M6R), the pyrrole rings present a similar conformation
as in R173W-ES2. However, in themutant structure, we observe a different conformation of the propionate side
chainof C1 than inwt-ES2 (PDB: 5M6R) (Figure 5), whereas this propionate forms an electrostatic andhydrogen-
bonding interaction network with Arg173 and Ser147, themutation R173W abolishes the interaction and in the
crystal structure the propionate is bent and is no longer in contact with the protein (Table 2 and Figure 5).DISCUSSION
Despite more than 500 AIP-associated HMBS variants discovered to date, little is known about their struc-
tural effects. Using high-resolution ESI FT-ICR MS and X-ray crystallography, we obtained crucial structural
information on two common AIP-associated mutations, R167W and R173W. Our results are an importantiScience 24, 102152, March 19, 2021 7
Figure 6. Schematic view of the interactions between the pyrrole rings and the hPBGD protein in the crystal
structures of wt-Eholo and R173W-ES2 mutant
(A) The hydrogen bond interactions of the DPM cofactor with the wt-hPBGD residues in the active site.
(B) The interactions between the pyrrole chain intermediate as seen in the crystal structure of the R173W-hPBGD mutant.
Side chain H-bond interactions (blue), H-bond interactions to main chain carbonyl oxygen (green) and H-bond




Articlestep toward understanding the pathogenic molecular mechanisms leading to AIP, as well as the pyrrole-
chain elongation-mechanism.
ESI FT-ICR MS allowed us to determine the distribution of the enzyme-intermediates in wt-hPBGD in a quanti-
tative manner, which has not been possible by other methods due to their limited resolution. The ES2 interme-
diate was themost abundant, whereas ESwas only found in a very small amount andES4 was not detected at all.
ES is kinetically less stable than ES2 or ES3, and ES2 accumulates during the reaction, in agreement with a slow
rateof theES2/ES3 step (Niemannetal., 1994;WarrenandJordan,1988). Thepresenceof theapoenzyme inwt-
hPBGD is remarkable and has not been observed before in any enzyme preparation is from prokaryote expres-
sion, as it is assumed tobeunstable and less structurally compact thanEholo (Awanet al., 1997; Scott et al., 1989).
Several arginine residues are conserved in PBGD across species. They are involved in or even crucial for either
catalysis (e.g.,Arg26), structural stability (e.g.,Arg251)or implicated in thecofactorbinding (Arg150) (Jordanand
Woodcock, 1991; Lander et al., 1991). Arg167 is one of the highly conserved residues andhas been proposed to
act as a gatekeeper for incoming substrates and to be important in breaking of the salt bridges in PBG prior to
catalysis (Brownlie et al., 1994; Bung et al., 2018; Gill et al., 2009; Shoolingin-Jordan et al., 2003). Missense mu-
tations of Arg167 affect both the affinity for PBG and the catalytic efficiency of the enzyme rather than instability
or misfolding (Bustad et al., 2013; Gill et al., 2009). The proposed effect of Arg167 mutations has recently been8 iScience 24, 102152, March 19, 2021
Table 1. Data collection and refinement statistics
wt-Eholo R173W-ES2
Data collection
PDB ID 7AAJ 7AAK
Resolution range 65.08–1.8 (1.864–1.8) 59.1–1.7 (1.761–1.7)
Space group P 21 21 21 P 21 21 21
Unit cell 81.2 84.6 108.9 90 90 90 81.2 86.1 107.4 90 90 90
Total reflections 528551 (52,834) 551220 (55,773)
Unique reflections 69,757 (6877) 83,105 (8199)
Multiplicity 7.6 (7.7) 6.6 (6.8)
Completeness (%) 98.9 (97.3) 99.47 (99.22)
Mean I/sigma(I) 10.24 (0.52) 15.48 (1.62)
Wilson B-factor 34.2 25.41
R-merge 0.095 (3.76) 0.068(1.56)
R-meas 0.102 (4.02) 0.074 (1.69)
CC1/2 0.99 (0.54) 1 (0.73)
Refinement
Reflections used in refinement 69,336 (6735) 82,994 (8182)
Reflections used for R-free 3510 (280) 4022 (398)
Rwork 24.9 (62.2) 18.3(34.8)
Rfree 29.4 (65.3) 21.2 (35.8)




Protein residues 647 669
RMSD (bonds) 0.007 0.007
RMSD (angles) 0.8 0.8
Validation
Ramachandran favored (%) 96.8 98.2
Ramachandran allowed (%) 2.2 1.8
Ramachandran outliers (%) 0 0
Clashscore 4.7 2.8







Articleattributed to the alteration of the binding site leading to both decreasedpyrrole chain elongation andblocking
of the HMB release (Bung et al., 2018). Our results clearly demonstrate that the elongation process is indeed
perturbed in the R167W mutant. This is consistent with the 30-fold higher Km and reduced Vmax relative to
thewt enzyme (Bustad et al., 2013), which results in slower elongation andaccumulation of the reaction interme-
diates (Bung et al., 2018; Gill et al., 2009; Jordan andWoodcock, 1991; Shoolingin-Jordan et al., 2003). Our re-
sults thus do not support the participation of Arg167 solely in product release, since the distribution of enzyme
intermediates was rather similar to the wt enzyme, and ES4 was not detected at all.
Arg173 is also highly conserved and is considered important for substrate docking to the active site (Louie
et al., 1996). The substitution of Arg173 with tryptophan introduces a large hydrophobic amino acid,iScience 24, 102152, March 19, 2021 9
Table 2. Interactions between protein and cofactor and/or substrate
Ring Wt-Eholo Interaction Ring R173W-ES2
Wt-ES2
(56MR) Interaction Mutations
C1 P101 P101 Pyrrole: p-stack –
T102 T102 Ac: H-bond –
V215 V215 Pr: H-bond
(main chain)
V215E/M (Bustad et al., 2013;
Schneider-Yin et al., 2008)
C2 S75A – Ac: vdW
K74A – Ac: H-bond –
– F77B Pyrrole: p-stack –
K98 K98 N: H-bond
(main chain)
K/R (Kauppinen et al., 1995)
D99 D99A Pyrrole: vdW D/G/H/N (Floderus et al., 2002;
Kauppinen and von und
zu Fraunberg, 2002)
S262 S262 Pr: H-bond –
S262B Ac: H-bond –
C1 K98 Ac: H-bond S1 K98 K98 Ac: H-bond K/R (Kauppinen et al., 1995)
D99 N: H-bond D99 D99 N: H-bond D/G/H/N (Floderus et al., 2002;
Kauppinen and von und
zu Fraunberg, 2002)




Pr: H-bond (main chain)
S147 S147 Ac: H-bond S/P (Whatley et al., 2009)
R149 Ac: Salt bridge R149 R149 Ac: Salt bridge R/L/P/Q (Delfau et al., 1991; Gu
et al., 1994; Kauppinen
et al., 1995; Yang
et al., 2008)
R150 Pr: Salt bridge – –
R173 Pr: Salt bridge – R173 Pr: Salt bridge R/G/Q/W (Delfau et al., 1990;
Kauppinen et al., 1992;
Mendez et al., 2009)
C2 S96 Pr: H-bond S2 S96 S96 Pr: H bond S/F (Kauppinen and von und
zu Fraunberg, 2002)
K98 Ac: H-bond K98 K98 Ac: H-bond K/R (Kauppinen et al., 1995)
D99 N: H-bond – D99A N: H-bond D/G/H/N (Floderus et al., 2002;
Kauppinen and von und
zu Fraunberg, 2002)
R150 Pr: Salt bridge R150 R150 Ac: Salt bridge –
A189 Ac: H-bond (main chain) A189 A189 Ac: H bond (main chain) –
R195 Pr: Salt bridge R195 R195 Pr: salt bridge R/C/H (Kauppinen et al., 1995;
Whatley et al., 2009)
Q217 Pr: vdW – Q217B Pr: vdW Q/H/L/R (Kuo et al., 2011; Puy et al.,
1997; Schneider-Yin et al.,
2000, 2006)
G218 G218 Pr: H bond
(main chain)
G/R (Yang et al., 2008)




Articlepredicted to hinder the cofactor and/or substrate interaction severely (Jordan and Woodcock, 1991). Both
ESI FT-ICR MS and X-ray crystallography show that this mutant accumulates the ES2 intermediate with a




Articlein the Eholo and of S1 in the ES2 state (Table 2 and Figure 6) (Pluta et al., 2018; Song et al., 2009), the trypto-
phan substitution does not hinder the binding of the cofactor and the reaction of the first two PBG sub-
strates. Hence, Arg173 is important for docking the third PBG substrate to the growing pyrrole chain.
Wt-hPBGD is very thermostable with a Tm of 74C (Bustad et al., 2013, 2020). As seen from our wt-Eholo
crystal structure and the reported wt-ES2 (PDB: 5M6R), this can be attributed to the strong hydrogen-
bonding network, in which the cofactor in Eholo or the pyrrole chain in ES2 engage Arg173 and interacting
residues in domain 2, including the cofactor-binding loop Leu257–Val263 in domain 1, with Cys261. In wt-
hPBGD, Arg173 might interact directly with S2 and the entering S3 through salt bridges with the acetate
and propionate side chains, substituting the interaction of Arg150 with S2 upon ES3 formation. The Arg-
to-Trp mutation results in a disruption of these interactions, partially explaining the large reduction of
thermal stability (Bustad et al., 2013). The conformational change seen in subunit B of the R173W-ES2
structure, where the bulky tryptophan residue turns away from the active site forcing a change in the
domain structure, probably also affects the loss in thermal stability (Figure S4). Together with its impor-
tant catalytic function, the role of Arg173 as a stabilizer in the active-site hydrogen-bonding network cor-
relates with the loss of the stability and activity upon Arg-to-Trp mutation and thus a severe AIP
outcome.
A striking structural feature of R173W-ES2 compared to wt-Eholo is that the cofactor-binding loop rearranges to
makemore space for the two incoming PBG substrates. Furthermore, S1 and S2 in ES2 occupy exactly the same
positions as C1 and C2 of the cofactor in Eholo with nearly identical interactions (Table 2 and Figure 6). Despite
the alteration of the interactions involving Arg173, the loop conformation and the pyrrole ring locations in our
R173W-ES2 structure correspond to the structure of wt-ES2 (5M6R; Figure 4B), strongly indicating a correct
conformation of the intermediate in the mutant. Thus, Arg173 participates in the interaction network involved
in the cofactor (C1) and the substrate (S1) binding in the Eholo andES2 states, respectively (Table 2 and Figures 5
and6) (Pluta et al., 2018), but is not important todefine theproper conformationof thepyrrole chain. Thesedata
corroborate thefindings fromESIFT-ICRMS, indicating thatArg173hasacrucial function in the thirdelongation
step fromES2 toES3. The catalytic defect is amajor consequenceof theR173Wmutation, despite havingmostly
been associated with a conformationally unstable protein and concomitantly reduced activity (Bustad et al.,
2013; Mustajoki andDesnick, 1985). Its role has, however, not been clearly elucidated in the previous investiga-
tions (Bung et al., 2018; Pluta et al., 2018), but its relevance in the interaction network in AIP pathology has been
discussed recently (Fu et al., 2019). Nevertheless, our results imply that Arg173 is essential for orienting the in-
termediate to a specific conformation, in either correctly positioning the pyrrole chain or docking an incoming
substrate, allowing the elongation from ES2 to ES3.
Recent in silico investigation of the interaction network during different intermediate states indicates dynamic
movementof theactive-site loop, aswell as specific interactionsbetween the loopandcofactor during theelon-
gation (Chakrabarty et al., 2020). However, the authors do not discuss the rearrangement of the cofactor-bind-
ing loop and how the interaction network is affected by this. The active-site loop (Ser57–Lys74) in R173W-ES2
adopts a different conformation than in the other crystal structures with electron density describing these res-
idues, i.e., AtPBGD (PDB: 4HTG) or wt-ES2 (PDB: 5M6R). In contrast to wt-ES2 (PDB: 5M6R), only a short helical
turn (Lys62–Thr66) is present in R173W-ES2, resulting in a more open conformation including only one clear
interaction between the loop and the substrate pyrroles, and Lys74 is hydrogen bonded to the acetate side
chain of the C2 pyrrole ring.
Based on the crystal structure of the wt-ES2 (PDB: 5M6R), Pluta et al. proposed a mechanism for the reaction
progression relying on the further movement on the cofactor-binding loop in the formation of ES3 and beyond
(Pluta et al., 2018). However, thismovementmight cause steric issues andmajor rearrangement of the a33 helix
as well as a disturbance of the network of hydrophobic interactions around this helix (Figure S5). Pluta et al. also
proposed that Arg26 and Asp99 are the only residues responsible for the pyrrole ring condensations as well as
for the release of the product, consistent with the recent computational work by Bung et al. (Bung et al., 2014).
The effect causedby theR173Wmutantion fitswith thismechanism; however, wedemonstrate by using this AIP
associatemutant rather than thewt enzyme that the substrate elongation fromES2 toES3 is crucially dependent
on Arg173. Although the Arg-to-Trp substitution does not seem to largely affect the structure of hPBGD in the
ES2-state, it affects the enzyme stability and the polypyrrole elongation beyond ES2, most probably due to the
disruption of the Arg173-centered interactions in domains 1 and 2 (Jordan andWoodcock, 1991; Lander et al.,




ArticleUnderstanding the details for the exact elongation mechanism remains unsolved. MD simulations propose a
mechanism relying on the protonation of incoming PBGs by the Arg26, and electrophilic addition and depro-
tonation in concert with Asp99 (Bung et al., 2018, 2019). However, these studies have not considered themove-
ment of the cofactor-binding loop upon the elongation; instead, they are relying on direct helicoidal elonga-
tion with only the active-site loop moving. This causes a steric problem for Arg26 and Asp99 where these
residues no longer are correctly positioned for the full catalysis cycle. The available crystal structures do not
provide detailed information on the dynamic movement of the active-site loop beyond the ES2 state, but
the wt-ES2 (PDB: 5M6R) and R173W-ES2 structures clearly show the movement of the cofactor-binding loop.
In conclusion, we show for the first time the direct effect of a mutation associated with AIP on the structure and
function of PBGD, revealing the importance of the interaction network around Arg173. Using X-ray crystallog-
raphy,we trapped thedisease-causingmutant R173W ina reaction intermediate andcombinedwithESI-FT-ICR
MS we pinpoint the crucial responsibility of Arg173 in the catalytic mechanism in stabilizing the structure and
ensuring proper interaction with the entering substrate to form ES3. Furthermore, our work highlights the
strength of ESI-FT-ICR MS as a high-resolution technique that quantifies co-existing ESn intermediates, repre-
senting an effective procedure to elucidate the catalytic effect of the AIP mutations. Hence, the distribution of
the intermediates for the R167W and R173Wmutants agrees with the severity of the respective associated AIP
phenotypeandprovides important insights into thecatalyticmechanismofPBGD.Wepropose that ashigh-res-
olution MS allows the direct analysis of intermediate distribution in PBGD, it could also be effective for drug
screeningof e.g., pharmacological chaperones (Bustadet al., 2020), aiming at the stabilization of PBGDandun-
stable AIP-associated mutants and/or the specific correction of altered distributions of enzyme intermediates.
Limitations of the study
This study characterized only two AIP-associated mutants. Investigating additional mutants will increase
our knowledge on genotype-phenotype relationships and will aid to elucidate the polypyrrole elongation
mechanism. The crystallization of the wt-PBGD was performed from a mixture of intermediates, and the
heterogeneity of the sample, as well as the flexible parts of the enzyme, such as the N-terminus and the
loop including residues 57–74, most likely affect the quality of the data. In the future, this could possibly
be overcome by crystallizing isolated intermediates. In addition, a crystal structure of PBGD in the ES3-state
and/or ES4-state is essential for understanding the complete mechanism.
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ring and to thank Johanna Hakanpää for the assistance in using the beamline. The use of the infrastructure
at the core facility BiSS at the University of Bergen is gratefully acknowledged. Prof. Juha Rouvinen (Univer-
sity of Eastern Finland) is thanked for critical reading of the manuscript and valuable comments.
AUTHOR CONTRIBUTIONS
Conceptualization: A.M., H.J.B., and J.J.; funding acquisition: A.M. and J.J.; investigation: H.J.B., J.P.K.,
and M.L.; project administration: A.M. and J.J.; resources: A.M., H.J.B, K.T., J.J, J.P.K. and I.K.; supervision:
A.M., J.J., and I.K.; validation: A.M., H.J.B., J.K.P., and J.J.; visualization: H.J.B, J.P.K., and J.J.; writing –
original draft: H.J.B.; writing – review & editing: H.J.B., J.P.K., A.M., J.J., K.T., and I.K.
DECLARATION OF INTERESTS
The authors declare no conflict of interest.
Received: September 11, 2020
Revised: December 3, 2020
Accepted: February 2, 2021
Published: March 19, 2021
REFERENCES
Anderson, P.M., and Desnick, R.J. (1980).
Purification and properties of uroporphyrinogen I
synthase from human erythrocytes. Identification
of stable enzyme-substrate intermediates. J. Biol.
Chem. 255, 1993–1999.
Andersson, C., Floderus, Y., Wikberg, A., and
Lithner, F. (2000). The W198X and R173W
mutations in the porphobilinogen deaminase
gene in acute intermittent porphyria have higher
clinical penetrance than R167W. A population-
basedstudy.Scand. J.Clin. Lab Invest.60, 643–648.
Awan, S.J., Siligardi, G., Shoolingin-Jordan, P.M.,
and Warren, M.J. (1997). Reconstitution of the
holoenzyme form of Escherichia coli
porphobilinogen deaminase from apoenzyme
with porphobilinogen and preuroporphyrinogen:
a study using circular dichroism spectroscopy.
Biochemistry 36, 9273–9282.
Azim, N., Deery, E., Warren, M.J., Wolfenden,
B.A., Erskine, P., Cooper, J.B., Coker, A., Wood,
S.P., and Akhtar, M. (2014). Structural evidence for
the partially oxidized dipyrromethene and
dipyrromethanone forms of the cofactor of
porphobilinogen deaminase: structures of the
Bacillus megaterium enzyme at near-atomic
resolution. Acta Crystallographica. Section D
Biol. Crystallogr. 70, 744–751.
Berry, A., Jordan, P.M., and Seehra, J.S. (1981). The
isolation and characterization of catalytically
competent porphobilinogen deaminase-
intermediate complexes. FEBS Lett. 129, 220–224.
Bonkovsky, H.L., Dixon, N., and Rudnick, S. (2019).
Pathogenesis and clinical features of the acute
hepatic porphyrias (AHPs). Mol. Genet. Metab.
128, 213–218.
Brons-Poulsen, J., Christiansen, L., Petersen, N.E.,
Horder, M., and Kristiansen, K. (2005).
Characterization of two isoalleles and three
mutations in both isoforms of purified
recombinant human porphobilinogen
deaminase. Scand. J. Clin. Lab Invest. 65, 93–105.Brownlie, P.D., Lambert, R., Louie, G.V., Jordan,
P.M., Blundell, T.L., Warren, M.J., Cooper, J.B.,
and Wood, S.P. (1994). The three-dimensional
structures of mutants of porphobilinogen
deaminase: toward an understanding of the
structural basis of acute intermittent porphyria.
Protein Sci. 3, 1644–1650.
Bung, N., Pradhan, M., Srinivasan, H., and Bulusu,
G. (2014). Structural insights into E. coli
porphobilinogen deaminase during synthesis
and exit of 1-hydroxymethylbilane. PLoSComput.
Biol. 10, e1003484.
Bung, N., Roy, A., Chen, B., Das, D., Pradhan, M.,
Yasuda,M., New,M.I., Desnick, R.J., andBulusu,G.
(2018). Human hydroxymethylbilane synthase:
molecular dynamicsof thepyrrole chain elongation
identifies step-specific residues that cause AIP.
Proc. Natl. Acad. Sci. U S A 115, E4071–E4080.
Bung,N., Roy, A., Priyakumar, U.D., andBulusu,G.
(2019). Computational modeling of the catalytic
mechanism of hydroxymethylbilane synthase.
Phys. Chem. Chem. Phys. 21, 7932–7940.
Bustad, H.J., Toska, K., Schmitt, C., Vorland, M.,
Skjaerven, L., Kallio, J.P., Simonin, S., Letteron, P.,
Underhaug, J., Sandberg, S., et al. (2020). A
pharmacological chaperone therapy for acute
intermittent porphyria. Mol. Ther. 28, 677–689.
Bustad, H.J., Vorland, M., Ronneseth, E.,
Sandberg, S., Martinez, A., and Toska, K. (2013).
Conformational stability and activity analysis of
two hydroxymethylbilane synthase mutants,
K132N and V215E, with different phenotypic
association with acute intermittent porphyria.
Biosci. Rep. 33, e00056.
Chakrabarty, B., Das, D., Bung, N., Roy, A., and
Bulusu, G. (2020). Network analysis of
hydroxymethylbilane synthase dynamics. J. Mol.
Graphics Model. 99, 107641.
Chen, B., Solis-Villa, C., Erwin, A.L., Balwani, M.,
Nazarenko, I., Phillips, J.D., Desnick, R.J., andYasuda, M. (2019). Identification and
characterization of 40 novel hydroxymethylbilane
synthase mutations that cause acute intermittent
porphyria. J. Inherit. Metab. Dis. 42, 186–194.
Delfau, M.H., Picat, C., De Rooij, F., Voortman, G.,
Deybach, J.C., Nordmann, Y., and Grandchamp,
B. (1991). Molecular heterogeneity of acute
intermittent porphyria: identification of four
additional mutations resulting in the CRIM-
negative subtype of the disease. Am. J. Hum.
Genet. 49, 421–428.
Delfau, M.H., Picat, C., de Rooij, F.W., Hamer, K.,
Bogard, M., Wilson, J.H., Deybach, J.C.,
Nordmann, Y., and Grandchamp, B. (1990). Two
different point G to A mutations in exon 10 of the
porphobilinogen deaminase gene are
responsible for acute intermittent porphyria.
J. Clin. Invest. 86, 1511–1516.
Floderus, Y., Shoolingin-Jordan, P.M., and
Harper, P. (2002). Acute intermittent porphyria in
Sweden. Molecular, functional and clinical
consequences of some new mutations found in
the porphobilinogen deaminase gene. Clin.
Genet. 62, 288–297.
Fu, Y., Jia, J., Yue, L., Yang, R., Guo, Y., Ni, X., and
Shi, T. (2019). Systematically analyzing the
pathogenic variations for acute intermittent
porphyria. Front. Pharmacol. 10, 1018.
Gill, R., Kolstoe, S.E., Mohammed, F., Al, D.B.A.,
Mosely, J.E., Sarwar, M., Cooper, J.B., Wood,
S.P., and Shoolingin-Jordan, P.M. (2009).
Structure of human porphobilinogen deaminase
at 2.8 A: the molecular basis of acute intermittent
porphyria. Biochem. J. 420, 17–25.
Grandchamp, B., De Verneuil, H., Beaumont, C.,
Chretien, S., Walter, O., and Nordmann, Y. (1987).
Tissue-specific expression of porphobilinogen
deaminase. Two isoenzymes from a single gene.




ArticleGu, X.F., de Rooij, F., Voortman, G., Te Velde, K.,
Deybach, J.C., Nordmann, Y., and Grandchamp,
B. (1994). Detection of eleven mutations causing
acute intermittent porphyria using denaturing
gradient gel electrophoresis. Hum. Genet. 93,
47–52.
Hadener, A., Matzinger, P.K., Battersby, A.R.,
McSweeney, S., Thompson, A.W., Hammersley,
A.P., Harrop, S.J., Cassetta, A., Deacon, A.,
Hunter, W.N., et al. (1999). Determination of the
structure of seleno-methionine-labelled
hydroxymethylbilane synthase in its active form
by multi-wavelength anomalous dispersion. Acta
Crystallographica. Section D Biol. Crystallogr. 55,
631–643.
Jordan, P.M., and Berry, A. (1981). Mechanism of
action of porphobilinogen deaminase. The
participation of stable enzyme substrate covalent
intermediates between porphobilinogen and the
porphobilinogen deaminase from
Rhodopseudomonas spheroides. Biochem. J.
195, 177–181.
Jordan, P.M., and Woodcock, S.C. (1991).
Mutagenesis of arginine residues in the catalytic
cleft of Escherichia coli porphobilinogen
deaminase that affects dipyrromethane cofactor
assembly and tetrapyrrole chain initiation and
elongation. Biochem. J. 280 (Pt 2), 445–449.
Kauppinen, R., Mustajoki, S., Pihlaja, H., Peltonen,
L., and Mustajoki, P. (1995). Acute intermittent
porphyria in Finland: 19 mutations in the
porphobilinogen deaminase gene. Hum. Mol.
Genet. 4, 215–222.
Kauppinen, R., Peltonen, L., Pihlaja, H., and
Mustajoki, P. (1992). CRIM-positive mutations of
acute intermittent porphyria in Finland. Hum.
Mutat. 1, 392–396.
Kauppinen, R., and von und zu Fraunberg, M.
(2002). Molecular and biochemical studies of
acute intermittent porphyria in 196 patients and
their families. Clin. Chem. 48, 1891–1900.
Kuo, H.C., Huang, C.C., Chu, C.C., Lee, M.J.,
Chuang, W.L., Wu, C.L., Wu, T., Ning, H.C., and
Liu, C.Y. (2011). Neurological complications of
acute intermittent porphyria. Eur. Neurol. 66,
247–252.
Lander, M., Pitt, A.R., Alefounder, P.R., Bardy, D.,
Abell, C., and Battersby, A.R. (1991). Studies on
the mechanism of hydroxymethylbilane synthase
concerning the role of arginine residues in
substrate binding. Biochem. J. 275 (Pt 2),
447–452.
Layer, G., Reichelt, J., Jahn, D., and Heinz, D.W.
(2010). Structure and function of enzymes in heme
biosynthesis. Protein Sci. 19, 1137–1161.
Louie, G.V., Brownlie, P.D., Lambert, R., Cooper,
J.B., Blundell, T.L., Wood, S.P., Malashkevich,
V.N., Hadener, A., Warren, M.J., and Shoolingin-
Jordan, P.M. (1996). The three-dimensional
structure of Escherichia coli porphobilinogen
deaminase at 1.76-A resolution. Proteins 25,
48–78.14 iScience 24, 102152, March 19, 2021Louie, G.V., Brownlie, P.D., Lambert, R., Cooper,
J.B., Blundell, T.L., Wood, S.P., Warren, M.J.,
Woodcock, S.C., and Jordan, P.M. (1992).
Structure of porphobilinogen deaminase reveals
a flexible multidomain polymerase with a single
catalytic site. Nature 359, 33–39.
Mendez, M., Moran-Jimenez, M.J., Gomez-
Abecia, S., Garcia-Bravo, M., Garrido-Astray,
M.C., Fontanellas, A., Poblete-Gutierrez, P.,
Frank, J., and Enriquez de Salamanca, R. (2009).
Identification and characterization of HMBS gene
mutations in Spanish patients with acute
intermittent porphyria. Cell. Mol. Biol. (Noisy-le-
grand) 55, 55–63.
Mustajoki, P., and Desnick, R.J. (1985). Genetic
heterogeneity in acute intermittent porphyria:
characterisation and frequency of
porphobilinogen deaminase mutations in
Finland. Br. Med. J. 291, 505–509.
Mustajoki, S., Laine, M., Lahtela, M., Mustajoki, P.,
Peltonen, L., and Kauppinen, R. (2000). Acute
intermittent porphyria: expression of mutant and
wild-type porphobilinogen deaminase in COS-1
cells. Mol. Med. 6, 670–679.
Niemann, A.C., Matzinger, P.K., and Hadener, A.
(1994). A kinetic-analysis of the reaction catalyzed
by (Hydroxymethyl)Bilane synthase. Helvetica
Chim. Acta 77, 1791–1809.
Pluta, P., Roversi, P., Bernardo-Seisdedos, G.,
Rojas, A.L., Cooper, J.B., Gu, S., Pickersgill, R.W.,
and Millet, O. (2018). Structural basis of pyrrole
polymerization in human porphobilinogen
deaminase. Bba-Gen Subjects 1862, 1948–1955.
Puy, H., Deybach, J.C., Lamoril, J., Robreau, A.M.,
Da Silva, V., Gouya, L., Grandchamp, B., and
Nordmann, Y. (1997). Molecular epidemiology
and diagnosis of PBG deaminase gene defects in
acute intermittent porphyria. Am. J. Hum. Genet.
60, 1373–1383.
Roberts, A., Gill, R., Hussey, R.J., Mikolajek, H.,
Erskine, P.T., Cooper, J.B., Wood, S.P., Chrystal,
E.J., and Shoolingin-Jordan, P.M. (2013). Insights
into the mechanism of pyrrole polymerization
catalysed by porphobilinogen deaminase: high-
resolution X-ray studies of the Arabidopsis
thaliana enzyme. Acta Crystallographica. Section
D Biol. Crystallogr. 69, 471–485.
Schneider-Yin, X., Bogard, C., Rufenacht, U.B.,
Puy, H., Nordmann, Y., Minder, E.I., andDeybach,
J. (2000). Identification of a prevalent nonsense
mutation (W283X) and two novel mutations in the
porphobilinogen deaminase gene of Swiss
patients with acute intermittent porphyria. Hum.
Hered. 50, 247–250.
Schneider-Yin, X., Szlendak, U., Lipniacka, A.I.,
Minder, E.I., and Gregor, A. (2006). Nine novel
mutations in the hydroxymethylbilane synthase
gene of Polish patients with acute intermittent
porphyria. Clin. Genet. 69, 284–286.
Schneider-Yin, X., Ulbrichova, D., Mamet, R.,
Martasek, P., Marohnic, C.C., Goren, A., Minder,
E.I., and Schoenfeld, N. (2008). Characterization of
two missense variants in the hydroxymethylbilane
synthase gene in the Israeli population, whichdiffer in their associations with acute intermittent
porphyria. Mol. Genet. Metab. 94, 343–346.
Scott, A.I., Clemens, K.R., Stolowich, N.J.,
Santander, P.J., Gonzalez, M.D., and Roessner,
C.A. (1989). Reconstitution of apo-
porphobilinogen deaminase: structural changes
induced by cofactor binding. FEBS Lett. 242,
319–324.
Scott, A.I., Roessner, C.A., Stolowich, N.J.,
Karuso, P., Williams, H.J., Grant, S.K., Gonzalez,
M.D., and Hoshino, T. (1988). Site-directed
mutagenesis and high-resolution NMR
spectroscopy of the active site of
porphobilinogen deaminase. Biochemistry 27,
7984–7990.
Shoolingin-Jordan, P.M., Al-Dbass, A., McNeill,
L.A., Sarwar, M., and Butler, D. (2003). Human
porphobilinogen deaminase mutations in the
investigation of themechanismof dipyrromethane
cofactor assembly and tetrapyrrole formation.
Biochem. Soc. Trans. 31, 731–735.
Shoolingin-Jordan, P.M., Warren, M.J., and
Awan, S.J. (1996). Discovery that the assembly of
the dipyrromethane cofactor of porphobilinogen
deaminase holoenzyme proceeds initially by the
reaction of preuroporphyrinogen with the
apoenzyme. Biochem. J. 316 (Pt 2), 373–376.
Solis, C., Martinez-Bermejo, A., Naidich, T.P.,
Kaufmann, W.E., Astrin, K.H., Bishop, D.F., and
Desnick, R.J. (2004). Acute intermittent porphyria:
studies of the severe homozygous dominant
disease provides insights into the neurologic
attacks in acute porphyrias. Arch. Neurol. 61,
1764–1770.
Song, G., Li, Y., Cheng, C., Zhao, Y., Gao, A.,
Zhang, R., Joachimiak, A., Shaw, N., and Liu, Z.J.
(2009). Structural insight into acute intermittent
porphyria. FASEB J. 23, 396–404.
Uchida, T., Funamizu, T., Chen, M., Tanaka, Y.,
and Ishimori, K. (2018). Heme binding to
porphobilinogen deaminase from Vibrio
cholerae decelerates the formation of 1-
hydroxymethylbilane. ACS Chem. Biol. 13,
750–760.
Warren, M.J., and Jordan, P.M. (1988).
Investigation into the nature of substrate binding
to the dipyrromethane cofactor of Escherichia
coli porphobilinogen deaminase. Biochemistry
27, 9020–9030.
Whatley, S.D., Mason, N.G., Woolf, J.R.,
Newcombe, R.G., Elder, G.H., and Badminton,
M.N. (2009). Diagnostic strategies for autosomal
dominant acute porphyrias: retrospective
analysis of 467 unrelated patients referred for
mutational analysis of the HMBS, CPOX, or PPOX
gene. Clin. Chem. 55, 1406–1414.
Yang, C.C., Kuo, H.C., You, H.L., Wang, J., Huang,
C.C., Liu, C.Y., Lan, M.Y., Stephenson, D.A., and
Lee, M.J. (2008). HMBS mutations in Chinese
patients with acute intermittent porphyria. Ann.
Hum. Genet. 72, 683–686.
iScience, Volume 24Supplemental informationCharacterization of porphobilinogen deaminase
mutants reveals that arginine-173 is crucial
for polypyrrole elongation mechanism
Helene J. Bustad, Juha P. Kallio, Mikko Laitaoja, Karen Toska, Inari Kursula, Aurora






Figure S1. Native mass spectrometry of wt-hPBGD (Related to Figure 2). The ESI FT-ICR 
mass spectrum was acquired with10 µM protein in 10 mM ammonium acetate pH 6.9. Narrow 
protein ion-charge state-distribution (12+ to 15+) is consistent with a tightly folded protein 
conformation. Peaks representing different enzyme-intermediates are assigned for charge state 
14+. The inset shows an expanded view on the charge state 14+ of the holoenzyme (E): 
experimental isotopic pattern (top); calculated isotopic patterns with the reduced (middle) or 
oxidized (bottom) dipyrromethane (DPM) cofactor present in the structure.  The peaks 
representing the most abundant isotopic masses (MW (m.a.)) are indicated by small arrows. 
Faint poorly resolved signals at m/z 3800–4500, possibly representing non-covalent hPBGD 
dimer are also indicated. 
  
 
Figure S2. A tryptic peptide map for wt-hPBGD (Related to Figure 2). The numbers in the 
red boxes indicate corresponding residues for each observed tryptic peptide (note: the 
numbering here corresponds to the produced protein with two additional N-terminal residues 
(GS), remnant from the expression vector construct). The blue box indicates the peptide with a 
covalently modified Cys261 residue (tetrapyrrole = ES2 intermediate). 
  
 
Figure S3. A tryptic peptide map for hPBGD-R173W (Related to Figure 2). The numbers 
in the red boxes indicate corresponding residues for each observed tryptic peptide (note: the 
numbering here corresponds to the produced protein with two additional N-terminal residues 
(GS), remnant from the expression vector construct). The blue box indicates the peptide with a 


























Figure S4. Comparison of the differences between the two molecules in the asymmetric 
unit in R173W-ES2 (Related to Figure 3). Molecule A (chain A) and molecule B (chain B) 
are shown in blue and light blue, respectively. Inset for domain 2, with the enlargement below, 
shows the alternative conformations of Ser146 and Trp173 as well as the rearrangement of in 
the α22 (residues 170–179) in subunit B.  
 
Figure S5. Cartoon representation of mutant R173W-ES2 (blue) and wt-Eholo (grey) 
superimposed showing the hydrophobic interactions anchoring the α33 in proximity of the 
cofactor binding loop (Related to Figure 3). Elongation product of R173W-ES2 is shown in 
green and DPM cofactor with of wt-Eholo is shown in brown. Hydrophobic residues on R173W-
ES2 between the C-terminal helix (α33) and the β-sheet (β31-3) are shown in tan. Upon the 




Table S1. List of tryptic peptides observed for wt-hPBGD (Related to Figure 2). The 
sequence in blue indicates the peptide with a covalently modified Cys261 residue 






(ppm) Residues (start-end) Sequence 
386.26396 386.2642 0 22 24 VIR 
445.2543 445.2537 -1 73 76 IGEK 
505.30252 505.3013 -2 254 257 AFLR 
594.33923 594.3377 -3 77 81 SLFTK 
673.35252 673.3507 -3 170 175 GNLNTR 
685.3891 685.3871 -3 153 158 AAQLQR 
799.45691 799.4552 -2 351 357 NILDVAR 
904.49974 904.4978 -2 143 151 SVVGTSSLR 
929.5091 929.507 -2 135 142 TLETLPEK 
1029.56994 1029.5679 -2 167 175 SIRGNLNTR 
1055.61139 1055.6087 -3 348 357 GAKNILDVAR 
1060.60153 1060.5989 -2 143 152 SVVGTSSLRR 
1173.6635 1173.6605 -3 35 45 IQTDSVVATLK 
1360.76376 1360.7602 -3 131 142 FVGKTLETLPEK 
1388.68765 1388.6837 -3 119 130 ENPHDAVVFHPK 
1477.76755 1477.7637 -3 351 363 NILDVARQLNDAH 
1733.92213 1733.9173 -3 348 363 GAKNILDVARQLNDAH 
1739.96241 1739.9584 -2 153 166 AAQLQRKFPHLEFR 
1791.77445 1791.7694 -3 1 19 GSMSGNGNAAATAEENSPKMR 
1815.99992 1815.9942 -3 135 151 TLETLPEKSVVGTSSLR 
1819.94175 1819.937 -3 119 134 ENPHDAVVFHPKFVGK 
1897.05478 1897.0495 -3 101 118 DLPTVLPPGFTIGAICKR 
1972.10014 1972.0953 -2 135 152 TLETLPEKSVVGTSSLRR 
2020.17372 2020.1681 -3 328 347 GPQLAAQNLGISLANLLLSK 
2102.10677 2102.1008 -3 179 197 LDEQQEFSAIILATAGLQR 
2160.14881 2160.1427 -3 230 248 DQDILDLVGVLHDPETLLR 
2230.20143 2230.1958 -3 178 197 KLDEQQEFSAIILATAGLQR 
2276.32759 2276.3216 -3 328 350 GPQLAAQNLGISLANLLLSKGAK 
2359.28078 2359.2747 -3 228 248 AKDQDILDLVGVLHDPETLLR 
2403.3552 2403.3486 -3 131 152 FVGKTLETLPEKSVVGTSSLRR 
2499.38561 2499.3809 -2 176 197 LRKLDEQQEFSAIILATAGLQR 
2500.45497 2500.4489 -2 324 347 NIPRGPQLAAQNLGISLANLLLSK 
2554.2737 2554.2672 -3 204 227 VGQILHPEECMYAVGQGALGVEVR 
2731.44078 2731.4334 -3 119 142 ENPHDAVVFHPKFVGKTLETLPEK 
2756.61002 2756.6025 -3 324 350 NIPRGPQLAAQNLGISLANLLLSKGAK 
2869.48535 2869.4783 -2 46 72 ASYPGLQFEIIAMSTTGDKILDTALSK 
2931.55694 2931.5488 -3 228 253 AKDQDILDLVGVLHDPETLLRCIAER 
3011.54833 3011.54 -3 178 203 KLDEQQEFSAIILATAGLQRMGWHNR 
3057.77481 3057.7663 -3 328 357 GPQLAAQNLGISLANLLLSKGAKNILDVAR 
3296.73031 3296.7214 -3 46 76 ASYPGLQFEIIAMSTTGDKILDTALSKIGEK 
3335.6183 3335.6114 -2 198 227 MGWHNRVGQILHPEECMYAVGQGALGVEVR 
3418.84888 3418.8395 -3 228 257 AKDQDILDLVGVLHDPETLLRCIAERAFLR 
3538.05541 3538.0471 -2 324 357 NIPRGPQLAAQNLGISLANLLLSKGAKNILDVAR 
3736.08447 3736.0748 -3 328 363 GPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH 
3774.03047 3774.0217 -2 119 152 RENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLR 
4025.13911 4025.1283 -3 35 72 IQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSK 
4080.21877 4080.2082 -3 82 118 ELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKR 
4216.36769 4216.3557 -3 324 363 NIPRGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH 
4452.38149 4452.3713 -2 35 76 IQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSKIGEK 
4500.44618 4500.4342 -3 77 117 SLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICK 
4580.45307 4580.4412 -3 30 72 SQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSK 
4656.54721 4656.5353 -3 77 118 SLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKR 
4708.54925 4708.5361 -3 29 72 KSQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSK 
5083.78831 5083.7784 -2 73 118 IGEKSLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKR 
5246.4875 5246.4739 -3 275 323 DGQLYLTGGVWSLDGSDSIQETMQATIHVPAQHEDGPEDDPQLVGITAR 
5547.80978 5547.7966 -2 178 227 KLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVR 
5971.97033 5971.9587 -2 228 274 AKDQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMK (ES2) 






Table S2. List of tryptic peptides observed for R173W-hPBGD (Related to Figure 2). 
The sequences in blue indicate the peptide with a covalently modified Cys261 residue 






(ppm) Residues (start-end) Sequence 
386.2641 386.2642 0 22 24 VIR 
431.2502 431.2492 2 25 28 VGTR 
445.2550 445.2537 3 73 76 IGEK 
449.2653 449.2638 3 131 134 FVGK 
498.2932 498.2914 4 324 327 NIPR 
505.3034 505.3013 4 254 257 AFLR 
559.3457 559.3442 3 25 29 VGTRK 
573.3254 573.3235 3 30 34 SQLAR 
590.2862 590.2846 3 249 253 CIAER 
594.3396 594.3377 3 77 81 SLFTK 
696.3211 696.3191 3 358 363 QLNDAH 
799.3582 799.3548 4 198 203 MGWHNR 
799.5046 799.5028 2 22 28 VIRVGTR 
841.4910 841.4882 3 152 158 RAAQLQR 
904.5002 904.4978 3 143 151 SVVGTSSLR 
927.6016 927.5978 4 22 29 VIRVGTRK 
929.5067 929.5070 0 135 142 TLETLPEK 
944.4900 944.4868 3 160 166 FPHLEFR 
967.5006 967.4975 3 82 89 ELEHALEK 
972.5154 972.5141 1 170 177 GNLNTWLR 
1021.5833 1021.5808 2 73 81 IGEKSLFTK 
1055.6128 1055.6087 4 348 357 GAKNILDVAR 
1060.6028 1060.5989 4 143 152 SVVGTSSLRR 
1072.5847 1072.5818 3 159 166 KFPHLEFR 
1086.6480 1086.6444 3 20 28 MRVIRVGTR 
1100.6130 1100.6091 4 170 178 GNLNTWLRK 
1173.6598 1173.6605 -1 35 45 IQTDSVVATLK 
1251.6853 1251.6823 2 90 100 NEVDLVVHSLK 
1360.7645 1360.7602 3 131 142 FVGKTLETLPEK 
1388.6879 1388.6837 3 119 130 ENPHDAVVFHPK 
1428.8047 1428.7990 4 159 169 KFPHLEFRSIR 
1477.7664 1477.7637 2 351 363 NILDVARQLNDAH 
1544.7885 1544.7848 2 118 130 RENPHDAVVFHPK 
1728.9760 1728.9734 2 30 45 SQLARIQTDSVVATLK 
1733.9201 1733.9173 2 348 363 GAKNILDVARQLNDAH 
1739.9624 1739.9584 2 153 166 AAQLQRKFPHLEFR 
1740.9509 1740.9484 1 101 117 DLPTVLPPGFTIGAICK 
1791.7720 1791.7694 1 1 19 GSMSGNGNAAATAEENSPK 
1815.9974 1815.9942 2 135 151 TLETLPEKSVVGTSSLR 
1819.9433 1819.9370 3 119 134 ENPHDAVVFHPKFVGK 
1972.0989 1972.0953 2 135 152 TLETLPEKSVVGTSSLRR 
1976.0431 1976.0381 3 118 134 RENPHDAVVFHPKFVGK 
2020.1705 2020.1681 1 328 347 GPQLAAQNLGISLANLLLSK 
2027.9875 2027.9874 0 46 64 ASYPGLQFEIIAMSTTGDK 
2078.9126 2078.9110 1 1 21 GSMSGNGNAAATAEENSPKMR 
2102.1069 2102.1008 3 179 197 LDEQQEFSAIILATAGLQR 
2160.1414 2160.1427 -1 230 248 DQDILDLVGVLHDPETLLR 
2201.1730 2201.1692 2 82 100 ELEHALEKNEVDLVVHSLK 
2230.1973 2230.1958 1 178 197 KLDEQQEFSAIILATAGLQR 
2247.2525 2247.2475 2 131 151 FVGKTLETLPEKSVVGTSSLR 
2276.3270 2276.3216 2 328 350 GPQLAAQNLGISLANLLLSKGAK 
2359.2785 2359.2747 2 228 248 AKDQDILDLVGVLHDPETLLR 
2403.3518 2403.3486 1 131 152 FVGKTLETLPEKSVVGTSSLRR 
2500.4516 2500.4489 1 324 347 NIPRGPQLAAQNLGISLANLLLSK 
2554.2674 2554.2672 0 204 227 VGQILHPEECMYAVGQGALGVEVR 
2571.1231 2571.1298 -3 258 274 HLEGGCSVPVAVHTAMK (ES2) 
2639.4745 2639.4719 1 135 158 TLETLPEKSVVGTSSLRRAAQLQR 
2731.4361 2731.4334 1 119 142 ENPHDAVVFHPKFVGKTLETLPEK 
2756.6053 2756.6025 1 324 350 NIPRGPQLAAQNLGISLANLLLSKGAK 
2869.4780 2869.4783 0 46 72 ASYPGLQFEIIAMSTTGDKILDTALSK 
2887.5403 2887.5345 2 118 142 RENPHDAVVFHPKFVGKTLETLPEK 
2931.5500 2931.5488 0 228 253 AKDQDILDLVGVLHDPETLLRCIAER 
2974.6231 2974.6202 1 90 117 NEVDLVVHSLKDLPTVLPPGFTIGAICK 
3011.5415 3011.5400 0 178 203 KLDEQQEFSAIILATAGLQRMGWHNR 
3057.7675 3057.7663 0 328 357 GPQLAAQNLGISLANLLLSKGAKNILDVAR 
3130.7239 3130.7213 1 90 118 NEVDLVVHSLKDLPTVLPPGFTIGAICKR 
3184.6994 3184.6993 0 170 197 GNLNTWLRKLDEQQEFSAIILATAGLQR 
3219.7042 3219.7074 -1 230 257 DQDILDLVGVLHDPETLLRCIAERAFLR 
3296.7213 3296.7214 0 46 76 ASYPGLQFEIIAMSTTGDKILDTALSKIGEK 
3335.6085 3335.6114 -1 198 227 MGWHNRVGQILHPEECMYAVGQGALGVEVR 
3418.8392 3418.8395 0 228 257 AKDQDILDLVGVLHDPETLLRCIAERAFLR 
3538.0508 3538.0471 1 324 357 NIPRGPQLAAQNLGISLANLLLSKGAKNILDVAR 
3540.9120 3540.9165 -1 167 197 SIRGNLNTWLRKLDEQQEFSAIILATAGLQR 
3736.0670 3736.0748 -2 328 363 GPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH 
3774.0233 3774.0217 0 118 151 RENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLR 
3774.0233 3774.0217 0 119 152 ENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLRR 
3924.1041 3924.1071 -1 82 117 ELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICK 
4025.1273 4025.1283 0 35 72 IQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSK 
4080.1971 4080.2082 -3 82 118 ELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKR 
4216.3556 4216.3557 0 324 363 NIPRGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH 
4500.4310 4500.4342 -1 77 117 SLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICK 
4580.4320 4580.4412 -2 30 72 SQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSK 
4656.5325 4656.5353 -1 77 118 SLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKR 
4708.5311 4708.5361 -1 29 72 KSQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSK 
4895.5283 4895.5314 -1 204 248 VGQILHPEECMYAVGQGALGVEVRAKDQDILDLVGVLHDPETLLR 
4927.6665 4927.6773 -2 73 117 IGEKSLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICK 
5083.7747 5083.7784 -1 73 118 IGEKSLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKR 
5246.4611 5246.4739 -2 275 323 DGQLYLTGGVWSLDGSDSIQETMQATIHVPAQHEDGPEDDPQLVGITAR (ES2) 
5450.8746 5450.8813 -1 82 130 ELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPK 
5547.7773 5547.7966 -3 178 227 KLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVR 
5676.8489 5676.8756 -5 198 248 MGWHNRVGQILHPEECMYAVGQGALGVEVRAKDQDILDLVGVLHDPETLLR 
5772.8026 5772.8266 -4 230 274 DQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMK (ES2) 
5971.9411 5971.9587 -3 228 274 AKDQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMK (ES2) 
6027.1990 6027.2085 -2 77 130 SLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPK 
6502.2782 6502.3002 -3 170 227 GNLNTWLRKLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVR 























Expression and purification of PBGD proteins 
Recombinant human wild-type PBGD and the mutants R167W and R173W were expressed in 
Escherichia coli BL21 (DE3)pLysS (Agilent technologies, Santa Clara, CA, USA) as 
glutathione S-transferase fusion proteins with a thrombin cleavage site (Bustad et al., 2013). 
The plasmid for protein expression was generously provided by Professor Pavel Martasek and 
Dana Ulbrichova as a pGEX4T-1-expression vector (Ulbrichova et al., 2006). Overnight 50 ml 
pre-cultures supplemented with 100 µM ampicillin and 34 µg/ml chloramphenicol were diluted 
into 950 ml Luria Bertani broth supplemented with the same antibiotics and 2 g/l glucose and 
grown at 37 °C in a shaking incubator at 200 rpm until OD600 ~0.8. Protein expression was 
induced by adding 1 mM IPTG (isopropyl thio-β-D-galactoside) and grown overnight at 28 °C, 
200 rpm. Cells were harvested by centrifugation at 4000 g and 4 °C for 15 min at, and stored at 
−80 ºC. Lysis was performed by sonication on ice after resuspension in lysis buffer (PBS; 
140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4; 1 mM EDTA, 0.5 mM 
PMSF, 1 mM benzamidine and cOmpleteTM Protease Inhibitor tablet (Roche Applied Science, 
Penzberg, Germany)), pH 7.4) with three 45-second rounds, 20 W output and 9 sec pulses. 
Soluble protein was obtained by centrifugation at 14 000 g for 45 min at 4 °C, and loaded onto 
a gluthatione-sepharose 4B column (GE Healthcare, Chicago, Illinois, USA) and washed with 
10 × CV of PBS containing 1 mM EDTA, followed by 2 × CV of PBS. The fusion protein was 
cleaved by adding thrombin (200 units/l) and incubating for 2 hrs at 4 °C on rotation, in 50 mM 
Tris-HCl, pH 8.0, containing 2 mM CaCl2, 1 mM DTT (dithiothreitol) and 150 mM NaCl. The 
protein were concentrated with Amicon Ultra centrifugal 30 kDa cut-off filters (Merck 
Millipore, Burlington, MA, USA), followed by size exclusion chromatography using a 
Superdex 200 HR16/60 column (GE Healthcare) in 20 mM HEPES with 150 mM NaCl, pH 
8.2. After cleavage of the fusion protein, two additional amino acid residues (glycine and serine, 
which form part of the cutting site to provide the necessary flexibility for efficient cleavage) 
remain attached at the protein N-terminus. The protein concentration was measured using a 
NanoDrop® spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) with the appropriate 
extinction coefficient predicted by the ExPASy ProtParam web server. The average molecular 
masses of apo- and holo-PBGD and its intermediates were predicted adding these residues to 
the ExPASy ProtParam web server based on the following wt-sequence (catalytic Cys261 
underlined); mutant residues were substituted where applicable: 
 (GS) MSGNGNAAATAEENSPKMRVIRVGTRKSQLARIQTDSVVATLKASYPGLQFEIIAMSTTG 






Prior to the MS experiments, all proteins samples were first desalted/buffer exchanged into 
10 mM ammonium acetate, pH 6.9, by using Sephadex G-25 M columns (PD-10; 
GE Healthcare) and concentrated using Vivaspin 5K centrifugal concentrators 
(GE Healthcare). The final protein concentrations were estimated by absorbance at 280 nm 
using sequence-derived extinction coefficients.  
Trypsin digestion was obtained by incubating an aliquot of the protein stock solution 
with TCPK-treated sequencing grade trypsin (Promega, Madison, WI, USA) at a 1:15 (w/w) 
enzyme-to-protein ratio at 37 °C for 4 h. The digestion was quenched by diluting the samples 
to the desired protein concentration with a solvent mixture of acetonitrile/water/acetic acid 
(49.5:49.5:1.0, v/v). The same solvent was used for the intact protein analysis in denaturing 
solution conditions. For the analysis in near-native solution conditions, 10 mM ammonium 
acetate, pH 6.9, was used instead.  
All FT-ICR MS experiments were performed on a 12-T Bruker Solarix-XR instrument 
(Bruker Daltonik GmbH, Bremen, Germany), equipped with an Apollo-II electrospray 
ionisation (ESI) source and dynamically harmonised ICR cell (Paracell). All samples were 
directly infused at a flow rate of 1.5 µl/min using a syringe pump. For intact mass analysis, a 
total of 300 time-domain transients (1 MWord each) were co-added for each spectrum and zero-
filled once to obtain final 2 MWord broadband data. This provided spectral resolution of 
roughly 200,000 (FWHM) at m/z 800 providing baseline-resolved protein signals. The final 
mass spectra were externally calibrated with respect to the ions of ESI-L Tuning Mix (Part no. 
G1969-85000; Agilent technologies). The instrument was operated, and the data were acquired 
with the use of solarixControl 2.0 software and the data were further processed and analysed 
with Bruker DataAnalysis 4.2 software. Spectral deconvolution for intact protein masses 
(reported as the most abundant isotopic masses throughout) was accomplished with a maximum 
entropy deconvolution (MaxEnt), while peptide monoisotopic masses were observed by using 
a SNAP2 peak-picking module. Sequence analysis (mass calculations) and tryptic peptide 
identifications were performed with GPMAW 10.0 software (Lighthouse Data). Briefly, 
monoisotopic peptide masses were matched against the protein sequence within a maximum 
mass error of 5 ppm with the covalently attached cofactor (DPM) or the polypyrrole as the 
variable modification. 
X-ray crystallography 
Both wt-hPBGD and R173W were concentrated to desired concentrations using Amicon Ultra 
centrifugal filters with 30 kDa cut-off (GE Healthcare) and filtered with 0.22 µm filter prior to 
the screening for the crystallisation conditions. Screening was performed at two initial 
temperatures, +8 and +20 °C, and two concentrations, 10 and 20 mg/ml, for both proteins using 
vapour diffusion method in SwissCI SD2 sitting drop plates and commercial screens; PACT 
premier and JSCG plus for Molecular Dimension, and Crystal Screen light and Peg/Ion from 
Hampton Research. Pipetting was done using Mosquito LCP crystallisation robot (TTP 
Labtech). 
 From the initial hits, the conditions were optimised for both proteins. Single crystals 
were obtained after 4–7 days for both proteins from similar conditions containing 20–25% 
polyethylene glycol 3350, 200–300 mM ammonium citrate at pH 5.1. The optimised 
concentrations for wt-PBGD and R173W were 10 and 14 mg/ml, respectively. The crystals for 
the wt-PBGD were more prone to grow in stacks, whereas R173W crystals were mostly single 
crystals. 
 For the data collection, crystals were cryoprotected by soaking for a few seconds in 
solution having 20% glycerol in addition to crystallisation solution prior to flash freezing. The 
MX data for the wt-PBGD and R173W was collected at the beamlines P13 and P14, 
respectively, operated by EMBL Hamburg at the PETRA III storage ring (DESY, Hamburg, 
Germany). The data was processed with XDS (Kabsch, 2010) and scaled with AIMLESS 
(Evans and Murshudov, 2013). Phaser-MR (McCoy et al., 2007) from PHENIX suite (Adams 
et al., 2010) was used for the molecular replacement using PBGD structure 3ECR as a search 
model. Structures were refined using phenix.refine (Afonine et al., 2012) and validated with 
MolProbity (Adams et al., 2010). Data collection and refinement statistics are shown in Table 
1. All 3D structure diagrams were prepared using Pymol (The PyMOL Molecular Graphics 
System, Version 2.0.4 Schrödinger, LLC.). The atomic coordinates and structure factor 
amplitudes have been submitted to the Protein Data Bank (PDB) under the accession codes 
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